Antineoplastic action of growth hormone-releasing hormone (GHRH) antagonists

Recent Patents on Anti-Cancer Drug Discovery

Volumn 7, Issue 1, 2012, Pages 56-63

  Siejka, Agnieszka ^a   Lawnicka, Hanna ^a   Melen Mucha, Gabriela ^a   Motylewska, Ewelina ^a   Komorowski, Jan ^a   Stepien, Henryk ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cancer therapy; GHRH; GHRH antagonists; IGF I; IGF II

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; GROWTH HORMONE RELEASING HORMONE ANTAGONIST; HORMONE ANTAGONIST; JMR 132; JV 1 10; JV 1 36; JV 1 38; MIA 602; MIA 610; MZ 4 243; MZ 4 71; MZ 5 156; MZ J 7 110; MZ J 7 114; MZ J 7 30; MZ J 7 46; MZ J 730; PEPTIDE HORMONE ANTAGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 83455233894     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489212798358010     Document Type: Review

References (78)

1. Reichlin S. Growth hormone content of pituitaries from rats with hypothalamic lesions. Endocrinology 1961; 69: 225-30.
2. Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature 1982; 300: 276-8.
3. Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 1982; 218: 585-7.
4. Bohlen P, Brazeau P, Bloch B, Ling N, Gaillard R, Guillemin R. Human hypothalamic growth hormone releasing factor (GRF): Evidence for two forms identical to tumor derived GRF-44-NH2 and GRF-40. Biochem Biophys Res Commun 1983; 114: 930-6.
5. Spiess J, Rivier J, Vale W. Characterization of rat hypothalamic growth hormone-releasing factor. Nature 1983; 303: 532-5.
6. Ling N, Esch F, Bohlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: Growth hormone-releasing factor. Proc Natl Acad Sci USA 1984; 81: 4302-6.
7. Mayo KE, Cerelli GM, Lebo RV, Bruce BD, Rosenfeld MG, Evans RM. Gene encoding human growth hormone-releasing factor precursor: structure, sequence, and chromosomal assignment. Proc Natl Acad Sci USA 1985; 82: 63-7.
8. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev 1986; 7: 223-53.
9. Vance ML. Growth-hormone-releasing hormone. Clin Chem 1990; 36: 415-20.
10. Thorner MO, Rivier J, Spiess J, Borges JL, Vance ML, Bloom SR, et al. Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man. Lancet 1983; 1: 24-8.
11. Vale W, Vaughan J, Yamamoto G, Spiess J, Rivier J. Effects of synthetic human pancreatic (tumor) GH releasing factor and somatostatin, triiodothyronine and dexamethasone on GH secretion in vitro. Endocrinology 1983; 112: 1553-5.
12. Brazeau P, Ling N, Bohlen P, Esch F, Ying SY, Guillemin R. Growth hormone releasing factor, somatocrinin, releases pituitary growth hormone in vitro. Proc Natl Acad Sci USA 1982; 79: 7909-13.
13. Sherwood NM, Krueckl SL, McRory JE. The origin and function of the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon superfamily. Endocr Rev 2000; 21: 619-70.
14. Mayo KE, Hammer RE, Swanson LW, Brinster RL, Rosenfeld MG, Evans RM. Dramatic pituitary hyperplasia in transgenic mice expressing a human growth hormone-releasing factor gene. Mol Endocrinol 1988; 2: 606-12.
15. Lin SC, Lin CR, Gukovsky I, Lusis AJ, Sawchenko PE, Rosenfeld MG. Molecular basis of the little mouse phenotype and implications for cell type-specific growth. Nature 1993; 364: 208-13.
16. Lin-Su K, Wajnrajch MP. Growth Hormone Releasing Hormone (GHRH) and the GHRH Receptor. Rev Endocr Metab Disord 2002; 3: 313-23.
17. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormonereleasing hormone: An emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008; 4: 33-43.
18. Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res 2000; 55: 237-66; discussion 66-7.
19. Petersenn S, Rasch AC, Heyens M, Schulte HM. Structure and regulation of the human growth hormone-releasing hormone receptor gene. Mol Endocrinol 1998; 12: 233-47.
20. Hohla F, Moder A, Mayrhauser U, Hauser-Kronberger C, Schally AV, Varga JL, et al. Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int J Oncol 2008; 33: 137-43.
21. Havt A, Schally AV, Halmos G, Varga JL, Toller GL, Horvath JE, et al. The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 2005; 102: 17424-9.
22. Steinmetz R, Zeng P, King DW, Walvoord E, Pescovitz OH. Peptides derived from pro-growth hormone-releasing hormone activate p38 mitogen-activated protein kinase in GH3 pituitary cells. Endocrine 2001; 15: 119-27.
23. Zeitler P, Siriwardana G. Stimulation of mitogen-activated protein kinase pathway in rat somatotrophs by growth hormone-releasing hormone. Endocrine 2000; 12: 257-64.
24. Pombo CM, Zalvide J, Gaylinn BD, Dieguez C. Growth hormonereleasing hormone stimulates mitogen-activated protein kinase. Endocrinology 2000; 141: 2113-9.
25. Lee EJ, Duan WR, Kotlar T, Jameson JL. Restoration of growth hormone-releasing hormone (GHRH) responsiveness in pituitary GH3 cells by adenovirus-directed expression of the human GHRH receptor. Endocrinology 2001; 142: 414-20.
26. Kiaris H, Schally AV, Kalofoutis A. Extrapituitary effects of the growth hormone-releasing hormone. Vitam Horm 2005; 70: 1-24.
27. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22: 248-91.
28. Khorram O, Garthwaite M, Golos T. The influence of aging and sex hormones on expression of growth hormone-releasing hormone in the human immune system. J Clin Endocrinol Metab 2001; 86: 3157-61.
29. Kiaris H, Koutsilieris M, Kalofoutis A, Schally AV. Growth hormone-releasing hormone and extra-pituitary tumorigenesis: therapeutic and diagnostic applications of growth hormonereleasing hormone antagonists. Expert Opin Investig Drugs 2003; 12: 1385-94.
30. Barabutis N, Schally AV. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 2008; 98: 1790-6.
31. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormonereleasing hormone receptors from human cancers. Proc Natl Acad Sci USA 2000; 97: 10561-6.
32. Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc Natl Acad Sci USA 2000; 97: 10555-60.
33. Siriwardana G, Bradford A, Coy D, Zeitler P. Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 2006; 20: 2010-9.
34. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 2007; 104: 5575-9.
35. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, et al. Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 2003; 100: 9512-7.
36. Barabutis N, Siejka A, Schally AV, Block NL, Cai R, Varga JL. Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. J Mol Endocrinol 2010; 44: 127-34.
37. Robberecht P, Coy DH, Waelbroeck M, Heiman ML, de Neef P, Camus JC, et al. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): Discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes. Endocrinology 1985; 117: 1759-64.
38. Jaffe CA, DeMott-Friberg R, Frohman LA, Barkan AL. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J Clin Endocrinol Metab 1997; 82: 634-7.
39. Kovacs M, Schally AV, Varga JL, Zarandi M. Endocrine and antineoplastic actions of growth hormone-releasing hormone antagonists. Curr Med Chem 2008; 15: 314-21.
40. Pollak MN, Polychronakos C, Richard M. Insulin-like growth factor I: A potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 1990; 82: 301-5.
41. Pollak M, Sem AW, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 1992; 84: 966-71.
42. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, et al. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 1994; 91: 12298-302.
43. Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K, et al. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 1997; 18: 423-30.
44. Varga JL, Schally AV, Csernus VJ, Zarandi M, Halmos G, Groot K, et al. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci USA 1999; 96: 692-7.
45. Varga JL, Schally AV, Horvath JE, Kovacs M, Halmos G, Groot K, et al. Increased activity of antagonists of growth hormonereleasing hormone substituted at positions 8, 9, and 10. Proc Natl Acad Sci USA 2004; 101: 1708-13.
46. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormonereleasing hormone and bombesin. Proc Natl Acad Sci USA 2003; 100: 15836-41.
47. Zarandi M, Varga JL, Schally AV, Horvath JE, Toller GL, Kovacs M, et al. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proc Natl Acad Sci USA 2006; 103: 4610-5.
48. Jaeger LB, Banks WA, Varga JL, Schally AV. Antagonists of growth hormone-releasing hormone cross the blood-brain barrier: a potential applicability to treatment of brain tumors. Proc Natl Acad Sci USA 2005; 102: 12495-500.
49. Dong, Z.X., Deoliveira, D.B. Antagonistic analogues of GHRH. WO2009108364 (2009).
50. Schally, A.V., Varga, J., Zarandi, M., Cai, R.Z., Block, N.L. Fluorinated GHRH antagonists. US2010092539 (2010) & US20110066230 (2011).
51. Bellyei S, Schally AV, Zarandi M, Varga JL, Vidaurre I, Pozsgai E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett 2010; 293: 31-40.
52. Pozsgai E, Schally AV, Zarandi M, Varga JL, Vidaurre I, Bellyei S. The effect of GHRH antagonists on human glioblastomas and their mechanism of action. Int J Cancer 2010; 127: 2313-22.
53. Schally, A.V., Varga, J., Zarandi, M. Antagonistic analogs of GHRH inhibiting IGF-I and -II. US6057422 (2000).
54. Schally, A.V., Varga, J., Zarandi, M., Cai, R.Z. Antagonistic analogs of GH RH. US7452865 (2008).
55. Zarandi, M., Schally, A.V. Analogues of hGH-RH(1-29)NH2 having antagonistic activity. US5550212 (1996).
56. Kineman RD. Antitumorigenic actions of growth hormonereleasing hormone antagonists. Proc Natl Acad Sci USA 2000; 97: 532-4.
57. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-28.
58. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, et al. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 2005; 90: 3614-21.
59. Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, et al. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 2001; 12: 761-8.
60. Szepeshazi K, Schally AV, Armatis P, Groot K, Hebert F, Feil A, et al. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2001; 142: 4371-8.
61. Siejka A, Lawnicka H, Komorowski J, Schally AV, Stepien T, Krupinski R, et al. GH-RH antagonist (MZ-4-71) inhibits VEGF secretion and proliferation of murine endothelial cells. Life Sci 2003; 72: 2473-9.
62. Heinrich E, Schally AV, Buchholz S, Rick FG, Halmos G, Mile M, et al. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. Prostate 2008; 68: 1763-72.
63. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 2007; 30: 1019-28.
64. Keller G, Schally AV, Groot K, Toller GL, Havt A, Koster F, et al. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 2005; 102: 10628-33.
65. Guo J, Schally AV, Zarandi M, Varga J, Leung PC. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol 2010; 8: 54.
66. Klukovits A, Schally AV, Szalontay L, Vidaurre I, Papadia A, Zarandi M, Varga JL, et al. Novel antagonists of growth hormonereleasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer 2011; Jul 12 DOI: 10.1002/cncr.26291 [Epub ahead of print]
67. Barabutis N, Siejka A, Schally AV. Growth hormone releasing hormone induces the expression of nitric oxide synthase. J Cell Mol Med 2011; 15: 1148-55.
68. Barabutis N, Schally AV. Antioxidant activity of growth hormonereleasing hormone antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA 2008; 105: 20470-5.
69. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, et al. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 2005; 41: 2735-44.
70. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. Int J Cancer 2004; 112: 570-6.
71. Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, et al. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of KRas, COX-2, and pAkt. Proc Natl Acad Sci USA 2007; 104: 18671-6.
72. Kiaris H, Schally AV. Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 1999; 96: 226-31.
73. 2+-dependent pathway. Proc Natl Acad Sci USA 2005; 102: 3435-40.
74. Schally, A.V., Barabutis, N. Antioxidant activity of GH-RH antagonists. US20100152114 (2010).
75. Barabutis N, Schally AV. Growth hormone-releasing hormone: extrapituitary effects in physiology and pathology. Cell Cycle 2010; 9: 4110-6.
76. Kiaris H, Chatzistamou I, Papavassiliou AG, Schally AV. Growth hormone-releasing hormone: Not only a neurohormone. Trends Endocrinol Metab 2011; 22: 311-7.
77. Siejka A, Schally AV, Block NL, Barabutis N. Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells. Prostate 2010; 70: 1087-93.
78. Stepien T, Lawnicka H, Komorowski J, Stepien H, Siejka A. Growth hormone-releasing hormone stimulates the secretion of interleukin 17 from human peripheral blood mononuclear cells in vitro. Neuro Endocrinol Lett 2010; 31: 852-6.